Easton Pharmaceuticals Announces It has Entered into Discussions For Distribution Agreement In East Asia
(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 09/15/11 -- Easton Pharmaceuticals Inc (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announced today the company has entered Into Discussions with 2 groups to distribute Viorra In South East Asia and surrounding markets.
As is the case in Mexico and other Latin American markets, East Asia represents a huge opportunity for VIORRA and the companies various other products based around its proprietary transdermal delivery system.
East Asia possesses a population upwards of 4 Billion people. The over-the-counter aspect of VIORRA and the fact the product possesses ingredients classified by the FDA as generally regarded as safe (GRAS) has transformed VIORRA into a very appealing product to people in these markets who repeatedly use over-the-counter products / herbal remedies more frequently than in North America. Products such as this have wide appeal and attraction to East Asian culture, which includes large markets such as China and India.
Presently the company has entered into discussions with two groups for the sale and distribution of VIORRA. Any agreements will involve an upfront payment to Easton, presently being discussed by all parties.
About Easton Pharmaceuticals Inc
Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.
The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.
Copyright ©2011 Easton Pharmaceuticals Inc. All rights reserved. Easton Pharmaceuticals, Easton Pharma and the Easton Pharmaceuticals logo, and all other Easton Pharmaceuticals company, product, and services names and slogans are trademarks or registered trademarks of Easton Pharmaceuticals Inc.
Contacts:
Easton Pharmaceuticals Inc.
+1(416) 619-0291 or +1(347) 284-0192
Fax: +1(888) 877-3723
Media relations:
Investor relations:
or
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.09.2011 - 13:00 Uhr
Sprache: Deutsch
News-ID 66347
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Alternative
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Easton Pharmaceuticals Announces It has Entered into Discussions For Distribution Agreement In East Asia"
steht unter der journalistisch-redaktionellen Verantwortung von
Easton Pharmaceuticals Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
